Optimizing hyaluronic acid therapy for dry eye disease: a systematic review, meta-analysis, and meta-regression by concentration and comparator type

HA eye drops, particularly formulations within the 0.15-0.18% range, were associated with meaningful improvements in patient-reported symptoms and were generally well tolerated, supporting their use as a first-line option for mild-to-moderate DED within the limitations of formulation heterogeneity.